Abstract
Increasing evidence shows that CC-chemokines promote inflammatory-driven angiogenesis,with little to no effect on hypoxia-mediated angiogenesis. Inhibition of the CC-chemokine class may therefore affect angiogenesis differently depending on the pathophysiological context.We compared the effect of CCchemokine inhibition in inflammatory and physiological conditions. In vitro, the broad-spectrum CCchemokine inhibitor "35K" inhibited inflammatory-induced endothelial cell proliferation, migration, and tubulogenesis, with more modest effects in hypoxia. In vivo, adenoviruses were used to overexpress 35K (Ad35K) and GFP (AdGFP, control virus). Plasma chemokine activity was suppressed by Ad35K in both models. In the periarterial femoral cuff model of inflammatory-driven angiogenesis, overexpression of 35K inhibited adventitial neovessel formation compared with control AdGFP-infused mice. In contrast, 35K preserved neovascularization in the hindlimb ischemia model and had no effect on physiological neovascularization in the chick chorioallantoic membrane assay. Mechanistically, 2 key angiogenic proteins (VEGF and hypoxia-inducible factor-1a) were conditionally regulated by 35K, such that expression was inhibited in inflammation but was unchanged in hypoxia. In conclusion, CC-chemokine inhibition by 35K suppresses inflammatory-driven angiogenesis while preserving physiological ischemia-mediated angiogenesis via conditional regulation of VEGF and hypoxia-inducible factor-1a. CC-chemokine inhibition may be an alternative therapeutic strategy for suppressing diseases associated with inflammatory angiogenesis without inducing the side effects caused by global inhibition.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | FASEB journal : official publication of the Federation of American Societies for Experimental Biology |
| Vol/bind | 31 |
| Udgave nummer | 3 |
| Sider (fra-til) | 1179-1192 |
| Antal sider | 14 |
| ISSN | 0892-6638 |
| DOI | |
| Status | Udgivet - mar. 2017 |
| Udgivet eksternt | Ja |